摘要
目的 对比研究TAC/AC-T化疗方案对HER-2阴性乳腺癌患者凝血功能的影响。方法 选取2015年3月-2018年12月在我院接受治疗的HER-2阴性乳腺癌患者106例,按照治疗方法不同分为TAC组和AC-T组,每组53例。两组患者分别采取相应的化疗方案进行治疗。评价两组患者的临床疗效、凝血功能及不良反应发生情况。结果 AC-T组患者临床治疗总有效率明显高于TAC组,差异具有统计学意义(P<0.05)。治疗后,TAC组和AC-T组PT、PLT较治疗前明显下降,差异具有统计学意义(P<0.05),而APTT、TT、FIB、DD无明显变化(P>0.05),凝血功能各项指标组间比较,差异均无统计学意义(P>0.05)。AC-T组红细胞减少、粒细胞减少、恶心、呕吐、腹泻、脱发及转氨酶升高的发生率明显低于TAC组,差异具有统计学意义(P<0.05);其它不良反应发生率组间比较无显著差异(P>0.05)。结论 TAC和AC-T方案对HER-2阴性乳腺癌患者均有较好的临床疗效,且AC-T治疗方案在临床疗效及安全性方面更具优势。两种化疗方案对患者的凝血功能均有一定影响,治疗过程中应密切关注患者凝血功能指标的变化,为其后期的恢复积极做好预防准备。
Objective To compare the effects of TAC/AC-T regimen on coagulation function of patients with HER-2-negative breast cancer. Methods A total of 106 patients with HER-2-negative breast cancer who received treatment in our hospital between March 2015 and December 2018 were selected and divided into TAC group and AC-T group according to different treatment methods. Each group had 53 cases. Patients in TAC group were given TAC regimen (docetaxel + adriamycin + cyclophosphamide). Those in AC-T group were given adriamycin and cyclophosphamide, and sequentially with docetaxel. The clinical efficacy, coagulation function and adverse reactions of the two groups were evaluated and compared between the two groups. Results The total effective rate of AC-T group was significantly higher than that of TAC group (P<0.05). Compared with before treatment, the levels of PT and PLT in TAC group and AC-T group decreased significantly after treatment (P< 0.05), but there were no significant differences in APTT, TT, FIB and DD indexes (P>0.05). Compared with TAC group, there was no significant difference in coagulation function between AC-T group and TAC group (P > 0.05). After treatment, the incidence of erythrocytopenia, granulocytopenia, nausea and vomiting, diarrhea, alopecia and elevated aminotransferase in AC-T group was significantly lower than that of the TAC group (P<0.05). There was no statistical difference in other adverse reactions between the two groups (P>0.05). Conclusion Both TAC and AC-T regimen have good clinical efficacy for HER-2-negative breast cancer patients. AC-T treatment has more advantages in clinical efficacy and safety. Both of the two chemotherapy schemes have certain effects on the coagulation function of patients. Close attention should be paid to the changes of coagulation index, so as to make positive preparations for the recovery of patients in the later stage.
作者
张铁
王丕琳
朱强
曲更宝
王林
ZHANG Tie;WANG Pilin;ZHU Qiang;QU Gengbao;WANG Lin(Department of Breast Surgery, Beijing Tiantan Hospital, Beijing, 100070, China)
出处
《肿瘤药学》
CAS
2019年第3期427-430,共4页
Anti-Tumor Pharmacy
基金
国家自然科学基金面上项目(81273642)
